COVID-19相关ARDS与非COVID-19相关ARDS早期AKI的流行病学与结局:两项全球前瞻性队列研究的启示
基于COVID-19危重症联盟(CCCC)全球数据集中1699例因COVID-19相关ARDS接受有创机械通气的患者,描述并比较其早期AKI的发生率、人口学特征、管理与结局与非COVID-19相关ARDS队列(LUNG-SAFE研究)的差异。结果显示,机械通气启动48小时内6.5%为1期、5.5%为2期、8.9%为3期AKI,79.1%无AKI;2期和3期AKI的28天和90天死亡风险均升高(HR 2.00和HR 1.95,p<0.001)。与非COVID-19 ARDS相比,COVID-19 ARDS各组休克发生率更低、心血管SOFA评分更低,但院内死亡率更高;且56%的AKI发生在最初48小时,而非COVID-19 ARDS为89%。
要点
- 在1699例COVID-19相关ARDS有创通气患者中,48小时内1期AKI占6.5%、2期占5.5%、3期占8.9%,79.1%无AKI。
- 2期AKI(HR 2.00,p<0.001)和3期AKI(HR 1.95,p<0.001)均与28天和90天死亡风险升高相关。
- 与非COVID-19 ARDS相比,COVID-19 ARDS各组院内死亡率更高:无AKI 30% vs 50%、1期38% vs 58%、2期56% vs 74%、3期52% vs 72%(p<0.001)。
- COVID-19 ARDS中56%的AKI发生在最初48小时,而非COVID-19 ARDS为89%。
- 3期AKI发生率在欧洲高收入国家较低,在中等收入国家患者中较高。
适用人群与场景
- CCCC数据集中因COVID-19相关ARDS接受有创机械通气且具备相关结局数据的1699例患者。
- 对照为非COVID-19相关ARDS队列(LUNG-SAFE研究)。
诊断标准与关键阈值
- 早期AKI定义为启动有创机械通气后48小时内发生的AKI,按1期、2期、3期分级。
研究设计与关键结果
- 研究类型为两项前瞻性全球队列研究(CCCC数据集与LUNG-SAFE研究)的比较分析;CCCC数据集共18964例患者,其中1699例COVID-19相关ARDS患者接受有创通气并有相关结局数据。
- COVID-19相关ARDS患者中,110例(6.5%)为1期AKI,94例(5.5%)为2期,151例(8.9%)为3期,1214例(79.1%)在启动有创机械通气48小时内无AKI。
- 发生AKI的患者年龄更大,更常合并高血压或慢性心脏病。
- AKI发生率存在地理经济差异:3期AKI在欧洲高收入国家发生率较低,在中等收入国家患者中发生率较高。
- 2期AKI(HR 2.00,p<0.001)和3期AKI(HR 1.95,p<0.001)的28天和90天死亡风险均升高。
- 与非COVID-19 ARDS相比,COVID-19 ARDS所有患者组休克发生率降低、心血管SOFA评分更低,但院内死亡率更差:无AKI 30% vs 50%、1期38% vs 58%、2期56% vs 74%、3期52% vs 72%(p<0.001)。
- AKI发生时间分布不同:COVID-19 ARDS中56%的AKI发生在最初48小时,而非COVID-19 ARDS为89%。
证据类型、等级与局限
- 证据类型:两项前瞻性全球队列研究的比较分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,AKI是COVID-19常见且严重的并发症,死亡率高,且因地理经济位置而异;COVID-19与非COVID-19 ARDS在AKI的血液动力学特征、发生时间和临床结局方面存在重要差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury (AKI) is a frequent and severe complication of both COVID-19-related acute respiratory distress syndrome (ARDS) and non-COVID-19-related ARDS. The COVID-19 Critical Care Consortium (CCCC) has generated a global data set on the demographics, management and outcomes of critically ill COVID-19 patients. The LUNG-SAFE study was an international prospective cohort study of patients with severe respiratory failure, including ARDS, which pre-dated the pandemic.
METHODS: The incidence, demographic profile, management and outcomes of early AKI in patients undergoing invasive mechanical ventilation for COVID-19-related ARDS were described and compared with AKI in a non-COVID-19-related ARDS cohort.
RESULTS: Of 18,964 patients in the CCCC data set, 1699 patients with COVID-19-related ARDS required invasive ventilation and had relevant outcome data. Of these, 110 (6.5%) had stage 1, 94 (5.5%) had stage 2, 151 (8.9%) had stage 3 AKI, while 1214 (79.1%) had no AKI within 48 h of initiating invasive mechanical ventilation. Patients developing AKI were older and more likely to have hypertension or chronic cardiac disease. There were geo-economic differences in the incidence of AKI, with lower incidence of stage 3 AKI in European high-income countries and a higher incidence in patients from middle-income countries. Both 28-day and 90-day mortality risk was increased for patients with stage 2 (HR 2.00, p < 0.001) and stage 3 AKI (HR 1.95, p < 0.001). Compared to non-COVID-19 ARDS, the incidence of shock was reduced with lower cardiovascular SOFA score across all patient groups, while hospital mortality was worse in all groups [no AKI (30 vs 50%), Stage 1 (38 vs 58%), Stage 2 (56 vs 74%), and Stage 3 (52 vs 72%), p < 0.001]. The time profile of onset of AKI also differed, with 56% of all AKI occurring in the first 48 h in patients with COVID-19 ARDS compared to 89% in the non-COVID-19 ARDS population.
CONCLUSION: AKI is a common and serious complication of COVID-19, with a high mortality rate, which differs by geo-economic location. Important differences exist in the profile of AKI in COVID-19 versus non-COVID-19 ARDS in terms of their haemodynamic profile, time of onset and clinical outcomes.
参考来源
- McNicholas BA, Rezoagli E, Simpkin AJ, et al. Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies. Crit Care. 2023. PMID: 36604753. doi:10.1186/s13054-022-04294-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。